Protocolo de manejo terapéutico del lupus eritematoso sistémico

  1. Melchor Díaz, S.
  2. de los Riscos, M.
  3. Rabadán Rubio, E.
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2017

Issue Title: Enfermedades del sistema inmune y reumatológicas (II) Lupus eritematoso. Esclerodermia. Enfermedad mixta del tejido correctivo

Series: 12

Issue: 25

Pages: 1467-1473

Type: Article

DOI: 10.1016/J.MED.2017.01.006 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

Introduction Systemic lupus erythematosus (SLE) is a very very heterogeneous disease that can affect multiple organs with differing degrees of severity, so it is important to know and manage the different therapeutic agents available to treat the different clinical manifestations; we must know their indications, posology and possible adverse effects in order to conduct an efficient and secure treatment. Treatment Treatment protocols for SLE, within the different clinical manifestations where they are applied, follow the goal of achieving remission of the disease, avoiding the exacerbations with maintenance therapies and preventing comorbidities, in order to preserve functioning of all implicated organs. Conclusions Good management of these therapies for the different and heterogeneous clinical manifestations were lupus is present will contribute to increasing quality of life and life expectancy in these patients, and also avoid comorbidities.

Bibliographic References

  • American College of Rheumatology Ad Hoc Committee on Systemic Lupus. Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum. 2004;50:3418-26.
  • Bertsias G, Joannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EU-LAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008;67:195-205.
  • Bertsias G, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH. Joint European League Against Rheumatism and European Renal Association European Dialysis and Transplant As-sociation (EULAR/ERA-EDATA) recommendations for the mana-gement of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771-82.
  • EULAR textbook on rheumatic diseases. Edición en español. vol. 5; Connective tissue diseases and vasculitis. D.L.: B12056-2014
  • Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M; Canadian Network For Improved Outcomes in Systemic Lupus. Steroid sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008;59:1796-804.
  • Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT. Mycophenolate mofetil or intravenous cyclophosphamide in for lupus nephritis. N Engl J Med. 2005;353:2219-28.
  • Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R. EULAR Recommendations for monitoring systemic lupus erythematosus patients in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269-74.
  • Pamfil C, Fanouriakis A, Damian L, Rinzis M, Sidiropoulos P, Tsivgoulis G. EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. Rheu-matology. 2015;54:1270-8.
  • Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929-39.
  • Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69: 20-8.
Data source: Dialnet